Keyphrases
Indonesia
100%
Leprosy
56%
Atopic Dermatitis
42%
Malaria
37%
Surabaya
30%
Leprosy Patients
26%
Risk Factors
22%
Plasmodium Falciparum
21%
Mycobacterium Leprae
17%
Photoaging
16%
Methotrexate
16%
Sumbawa
14%
Randomized Controlled Trial
13%
Plantar Ulcer
12%
Epigallocatechin-3-gallate
12%
Adipose-derived Mesenchymal Stem Cells (ADMSCs)
12%
Plasmodium Vivax
12%
Psoriasis Vulgaris
11%
AIDS/HIV
11%
Balb C Mice
10%
Outpatient Clinic
10%
Lombok
10%
COVID-19
10%
Academic Hospital
9%
Psoriasis
9%
Interleukin-10
9%
Erythema Nodosum Leprosum
9%
Tertiary Hospital
9%
Glucose-6-phosphate Dehydrogenase (G6PD)
9%
Prednisolone
9%
Mesenchymal Stem Cell-conditioned Medium
9%
Central Kalimantan
9%
Skin Prick Test
9%
Ulcer
9%
Malaria Incidence
9%
Healing
9%
Disability
8%
General Hospital
8%
Malaria Control
8%
Ultraviolet-B (UV-B)
8%
Lombok Island
8%
SCORing Atopic Dermatitis (SCORAD)
8%
Growth Factors
8%
Interleukin-17 (IL-17)
8%
Transepidermal Water Loss
7%
House Dust Mite
7%
Venereology
7%
Moderate-to-severe Psoriasis
7%
Meta-analysis
6%
Allergen
6%
South Kalimantan
6%
Wistar Rats
6%
House Dust Mite Allergen
6%
Gauze Dressing
6%
Indonesian Batik
6%
Batik Worker
6%
Tinea Capitis
6%
Soil-transmitted Helminth Infections
6%
Xerosis Cutis
6%
Ceramide
6%
Bali Indonesia
6%
Scratching Behavior
6%
Double-blind Randomized Clinical Trial
6%
Toxoplasma Gondii (T. gondii)
6%
COVID-19 Pandemic
6%
Sequestration
6%
Placenta
6%
Nystatin
6%
Vulvovaginal Candidiasis
6%
Vitiligo
6%
Regency
6%
Experimental Cerebral Malaria
6%
Malaria-endemic Countries
6%
Gresik
6%
Acanthamoeba
6%
Prevalence Factors
6%
Diffuse Lepromatous Leprosy
6%
Falciparum Malaria
6%
T Cells
6%
Syphilis
6%
Indonesian
5%
Acidity
5%
Framycetin
5%
Disease Severity
5%
Psoriasis Therapy
5%
Healthcare Workers
5%
Hand Dermatitis
5%
Vascular Endothelial Growth Factor
5%
Allelic Variation
5%
Clinical Improvement
5%
STH Infection
5%
Hypoxia-inducible factor-1α (HIF-1α)
5%
Zone of Inhibition
5%
Interleukin-2
5%
Interleukin-1β
5%
M. Lepromatosis
5%
Kalimantan
5%
Pharmacology, Toxicology and Pharmaceutical Science
Atopic Dermatitis
31%
Diseases
23%
Infection
22%
Photoaging
13%
Ulcer
13%
Elimination
13%
Randomized Controlled Trial
12%
Plantar Ulcer
12%
Epigallocatechin Gallate
12%
Methotrexate
12%
Prevalence
12%
Malaria Falciparum
11%
Retrospective Study
11%
Plasmodium falciparum
10%
Allergen
10%
Psoriasis
10%
Dermatitis
8%
Plasmodium
8%
Mixed Infection
8%
Malaria
8%
Cytokine
8%
Psoriasis Vulgaris
7%
Side Effect
7%
Microscopy
6%
Anti-Inflammatory Drug
6%
Adverse Event
6%
Prednisolone
6%
Xerosis
6%
Cerebral Malaria
6%
Pyrimethamine Plus Sulfadoxine
6%
Plasmodium Vivax Malaria
6%
HIV
6%
Candida
6%
Nystatin
6%
Coronavirinae
6%
Glucose 6 Phosphate Dehydrogenase
6%
Immunoglobulin E
6%
Framycetin
5%
Growth Factor
5%
Receptor
5%
Antimalarial Agent
5%
Clinical Trial
5%
Medicine and Dentistry
Diseases
25%
Retrospective Study
20%
Infection
17%
COVID-19
13%
Photoaging
12%
Psoriasis
12%
Methotrexate
12%
Mixed Infection
10%
Cross Sectional Study
10%
Randomized Controlled Trial
10%
Epigallocatechin Gallate
9%
Mesenchymal Stem Cell
9%
Plantar Ulcer
9%
Erythema Nodosum Leprosum
9%
Outpatient
9%
Mycosis
8%
Mycobacterium leprae
8%
Malaria Falciparum
8%
Ulcer
8%
Diagnosis
7%
Clinical Trial
6%
Public Health
6%
Tinea Capitis
6%
Amnion
6%
Plasmodium Vivax Malaria
6%
Human Immunodeficiency Virus
6%
Vitiligo
6%
Phototherapy
6%
Lepromatous Leprosy
6%
Quality of Life
6%
Dermatology
6%
Prevalence
5%
Rifampicin
5%
Medical Record
5%
Venereology
5%
Mycobacteria
5%